ANDA Reviews: Inspector General Weighs In, But Progress Depends On Congress
Executive Summary
A report by the HHS Office of Inspector General on FDA's review process for generic drugs illuminates the challenges the agency faces, but reaction to the report underscores the impression that complete resolution of the issue will require Congressional intervention
You may also be interested in...
Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority
FDA put its new labeling authority under the FDA Amendments Act on public display June 16 by directing makers of conventional antipsychotics to add to their drugs' prescribing information a boxed warning about use in elderly patients with dementia
Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority
FDA put its new labeling authority under the FDA Amendments Act on public display June 16 by directing makers of conventional antipsychotics to add to their drugs' prescribing information a boxed warning about use in elderly patients with dementia
180-Day Exclusivity Decision On Acarbose Illustrates Importance Of ANDA Quality
FDA's decision to deny Cobalt 180-day exclusivity for its ANDA of acarbose (Bayer's diabetes treatment Precose) illustrates the importance for generic firms of submitting high-quality applications